More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$608333748
EPS
-2.7
P/E ratio
--
Price to sales
8
Dividend yield
--
Beta
2.909515
Previous close
$11.29
Today's open
$11.33
Day's range
$10.54 - $11.49
52 week range
$6.96 - $16.93
show more
CEO
David Kirn
Employees
196
Headquarters
Emeryville, CA
Exchange
Nasdaq Global Select
Shares outstanding
56379402
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
4D Molecular Therapeutics, Inc. (FDMT) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
4D Molecular Therapeutics, Inc. ( FDMT ) Stifel 2026 Healthcare Conference 2026 November 11, 2026 8:00 AM EST Company Participants Christopher Simms - Chief Commercial & Business Officer Kristian Humer - CFO and Principal Financial & Accounting Officer Presentation Unknown Analyst All right. Good morning, everyone.
Seeking Alpha • Nov 14, 2026

4DMT Announces New Employment Inducement Grants
EMERYVILLE, Calif., Nov. 13, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on November 10, 2026, the compensation committee of the Company's board of directors granted one new non-executive employee 21,800 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company's 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
GlobeNewsWire • Nov 13, 2026

4DMT Reports Third Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respectively Presented 2-year data from PRISM and SPECTRA clinical trials of 4D-150 in wet AMD and DME, highlighting durable clinical activity and favorable, predictable safety profile Initiated 4SIGHT Global Phase 3 clinical trial of 4D-150 in DME, advancing 4D-150 into second multi-billion-dollar retinal disease market with significant unmet need Strengthened regulatory affairs and quality teams through the hire of Eric Floyd, PhD, MBA, as Chief Regulatory & Quality Officer $375 million in cash, cash equivalents and marketable securities expected to fund current operating plan into second half of 2028 EMERYVILLE, Calif., Nov. 12, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with the potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported Q3 2026 financial results, provided operational highlights and outlined expected upcoming milestones.
GlobeNewsWire • Nov 12, 2026

4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Tops Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.08 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to a loss of $1.01 per share a year ago.
Zacks Investment Research • Nov 13, 2026

4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
4D Molecular Therapeutics, Inc. (FDMT) Presents at 3rd Annual Guggenheim Healthcare Innovation Conference Transcript
Seeking Alpha • Nov 11, 2026

4DMT to Participate in Upcoming Investor Conferences
EMERYVILLE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will present and participate in one-on-one meetings at upcoming investor conferences in November and December: Guggenheim 3 rd Annual Healthcare Innovation Conference: Tuesday, November 10, 2026; Fireside chat at 4:30 p.m.
GlobeNewsWire • Nov 3, 2026

4D Molecular Therapeutics, Inc. (FDMT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
4D Molecular Therapeutics (FDMT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Nov 2, 2026

4D Molecular Therapeutics Targets Wet AMD Injection Burden With 4D-150 Gene Therapy
4D Molecular Therapeutics NASDAQ: FDMT used its first Investor Day to outline its development and commercial plans for 4D-150, an investigational intravitreal gene therapy for wet age-related macular degeneration, or wet AMD. Company executives and retina specialists described the therapy as a potential one-time “backbone” treatment intended to provide continuous disease control while reducing the burden of repeat anti-VEGF injections.
MarketBeat • Oct 22, 2026

4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript
4D Molecular Therapeutics, Inc. (FDMT) Analyst/Investor Day Transcript
Seeking Alpha • Oct 21, 2026

4DMT to Host Investor Day on October 21, 2026
Company to share insights on the advancing clinical profile and commercial vision for 4D-150 Renowned retinal experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Carl C.
GlobeNewsWire • Oct 5, 2026

¹ Disclosures

Open an M1 investment account to buy and sell 4D Molecular Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.